Vanguard disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares in Chemours (CC)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.
Positive
- None.
Negative
- None.
FAQ
What does Vanguard report for Chemours (CC) ownership in this amendment?
The filing reports 0 shares (0%) of Chemours common stock. This amendment states Vanguard holds no sole or shared voting or dispositive power over Chemours shares as reported.
Why are Vanguard subsidiaries reporting separately for Chemours (CC)?
Vanguard undertook an internal realignment effective January 12, 2026, and in reliance on SEC Release No. 34-39538, certain subsidiaries/divisions now report beneficial ownership separately from The Vanguard Group, Inc.
Who signed the Schedule 13G/A amendment for Vanguard on Chemours (CC)?
Ashley Grim, Head of Global Fund Administration, signed the amendment on 03/26/2026. The filing includes Vanguard's Malvern, Pennsylvania business address.
Does this amendment show any Vanguard voting or dispositive power for Chemours (CC)?
No; the amendment lists 0 for sole and shared voting power and 0 for sole and shared dispositive power. Vanguard reports no beneficial ownership in the class in this filing.